IL232173A0 - Cancer antigen presenting vaccine with gamma interferon - Google Patents
Cancer antigen presenting vaccine with gamma interferonInfo
- Publication number
- IL232173A0 IL232173A0 IL232173A IL23217314A IL232173A0 IL 232173 A0 IL232173 A0 IL 232173A0 IL 232173 A IL232173 A IL 232173A IL 23217314 A IL23217314 A IL 23217314A IL 232173 A0 IL232173 A0 IL 232173A0
- Authority
- IL
- Israel
- Prior art keywords
- antigen presenting
- cancer vaccine
- gamma interferon
- presenting cancer
- interferon
- Prior art date
Links
- 102000008070 Interferon-gamma Human genes 0.000 title 1
- 108010074328 Interferon-gamma Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 229940044627 gamma-interferon Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549681P | 2011-10-20 | 2011-10-20 | |
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| PCT/US2012/061294 WO2013059778A2 (en) | 2011-10-20 | 2012-10-22 | Antigen presenting cancer vaccine with gamma interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL232173A0 true IL232173A0 (en) | 2014-06-30 |
Family
ID=48141460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232173A IL232173A0 (en) | 2011-10-20 | 2014-04-22 | Cancer antigen presenting vaccine with gamma interferon |
| IL232172A IL232172A0 (en) | 2011-10-20 | 2014-04-22 | Antigen presenting cancer vaccine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232172A IL232172A0 (en) | 2011-10-20 | 2014-04-22 | Antigen presenting cancer vaccine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9555058B2 (enExample) |
| EP (2) | EP2768519A4 (enExample) |
| JP (2) | JP2014530627A (enExample) |
| KR (2) | KR20150004791A (enExample) |
| CN (5) | CN105999249A (enExample) |
| AU (2) | AU2012325758A1 (enExample) |
| CA (2) | CA2852967A1 (enExample) |
| HK (2) | HK1201175A1 (enExample) |
| IL (2) | IL232173A0 (enExample) |
| SG (4) | SG11201401632WA (enExample) |
| WO (2) | WO2013059778A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865830B1 (fr) | 2004-01-30 | 2006-05-19 | Neopost Ind | Systeme d'affranchissement de courrier a mode d'impression externe securise |
| SG11201401632WA (en) * | 2011-10-20 | 2014-05-29 | California Stem Cell Inc | Antigen presenting cancer vaccine |
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| CN107109365A (zh) * | 2014-07-17 | 2017-08-29 | 布莱恩·J·赫尔尼奇 | 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗 |
| AU2017261353A1 (en) * | 2016-05-05 | 2018-11-08 | Nantomics, Llc | Checkpoint failure and methods therefor |
| EP3582793A4 (en) * | 2017-02-17 | 2020-12-16 | Aivita Biomedical, Inc. | METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS |
| WO2024107624A1 (en) * | 2022-11-14 | 2024-05-23 | Shattuck Labs, Inc. | Methods of overcoming resistance to checkpoint inhibitor therapies |
| CN118441033B (zh) * | 2024-04-24 | 2025-06-20 | 广西医科大学 | HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU669379B2 (en) * | 1992-09-07 | 1996-06-06 | Kyowa Hakko Kirin Co., Ltd. | Humanized antibodies |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| AU2872199A (en) | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
| ES2340358T3 (es) | 1999-10-15 | 2010-06-02 | Baylor Research Institute | Uso de lineas celulares alogenicas para cargar celulas que presentan antigenos para elicitar respuestas inmunes. |
| US7015205B1 (en) * | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| US7771998B2 (en) * | 2001-11-29 | 2010-08-10 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
| GB0130720D0 (en) * | 2001-12-21 | 2002-02-06 | Serono Internat S A | Proteins |
| CN1443778A (zh) * | 2002-03-13 | 2003-09-24 | 上海中信国健药业有限公司 | 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物 |
| JP5623004B2 (ja) | 2004-10-25 | 2014-11-12 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞 |
| WO2007016340A2 (en) * | 2005-07-29 | 2007-02-08 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| CA2628477A1 (en) * | 2005-11-07 | 2007-05-10 | Bc Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| CN101511384A (zh) * | 2006-06-30 | 2009-08-19 | 贝勒研究院 | 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞 |
| AR060424A1 (es) | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
| SG11201401632WA (en) | 2011-10-20 | 2014-05-29 | California Stem Cell Inc | Antigen presenting cancer vaccine |
-
2012
- 2012-10-22 SG SG11201401632WA patent/SG11201401632WA/en unknown
- 2012-10-22 CN CN201610301904.7A patent/CN105999249A/zh active Pending
- 2012-10-22 CA CA2852967A patent/CA2852967A1/en not_active Abandoned
- 2012-10-22 CN CN201280051799.6A patent/CN103917246A/zh active Pending
- 2012-10-22 KR KR1020147013355A patent/KR20150004791A/ko not_active Withdrawn
- 2012-10-22 JP JP2014537358A patent/JP2014530627A/ja active Pending
- 2012-10-22 US US14/352,983 patent/US9555058B2/en not_active Expired - Fee Related
- 2012-10-22 KR KR1020147013353A patent/KR20150016200A/ko not_active Withdrawn
- 2012-10-22 JP JP2014537355A patent/JP2014533938A/ja active Pending
- 2012-10-22 SG SG10201602424RA patent/SG10201602424RA/en unknown
- 2012-10-22 HK HK15101635.2A patent/HK1201175A1/xx unknown
- 2012-10-22 SG SG11201401631VA patent/SG11201401631VA/en unknown
- 2012-10-22 CN CN201610218244.6A patent/CN105861437A/zh not_active Withdrawn
- 2012-10-22 SG SG10201508535RA patent/SG10201508535RA/en unknown
- 2012-10-22 WO PCT/US2012/061294 patent/WO2013059778A2/en not_active Ceased
- 2012-10-22 AU AU2012325758A patent/AU2012325758A1/en not_active Abandoned
- 2012-10-22 HK HK15101637.0A patent/HK1201176A1/xx unknown
- 2012-10-22 EP EP12841839.9A patent/EP2768519A4/en not_active Withdrawn
- 2012-10-22 CN CN201280051821.7A patent/CN103957925A/zh active Pending
- 2012-10-22 CN CN201510706438.6A patent/CN105288602A/zh active Pending
- 2012-10-22 US US14/352,982 patent/US20140308316A1/en not_active Abandoned
- 2012-10-22 AU AU2012325764A patent/AU2012325764A1/en not_active Abandoned
- 2012-10-22 WO PCT/US2012/061306 patent/WO2013059784A1/en not_active Ceased
- 2012-10-22 CA CA2852960A patent/CA2852960A1/en not_active Abandoned
- 2012-10-22 EP EP12842230.0A patent/EP2768534A4/en not_active Withdrawn
-
2014
- 2014-04-22 IL IL232173A patent/IL232173A0/en unknown
- 2014-04-22 IL IL232172A patent/IL232172A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105288602A (zh) | 2016-02-03 |
| AU2012325758A1 (en) | 2014-04-24 |
| SG10201602424RA (en) | 2016-05-30 |
| HK1201176A1 (en) | 2015-08-28 |
| CN103917246A (zh) | 2014-07-09 |
| NZ623917A (en) | 2016-09-30 |
| CN105861437A (zh) | 2016-08-17 |
| SG11201401631VA (en) | 2014-05-29 |
| JP2014530627A (ja) | 2014-11-20 |
| HK1201175A1 (en) | 2015-08-28 |
| EP2768534A1 (en) | 2014-08-27 |
| CA2852967A1 (en) | 2013-04-25 |
| AU2012325764A1 (en) | 2014-04-24 |
| NZ623915A (en) | 2016-02-26 |
| EP2768519A4 (en) | 2015-07-01 |
| WO2013059778A2 (en) | 2013-04-25 |
| SG10201508535RA (en) | 2015-11-27 |
| CN103957925A (zh) | 2014-07-30 |
| KR20150016200A (ko) | 2015-02-11 |
| US20140314814A1 (en) | 2014-10-23 |
| WO2013059784A1 (en) | 2013-04-25 |
| EP2768534A4 (en) | 2015-04-01 |
| CA2852960A1 (en) | 2013-04-25 |
| IL232172A0 (en) | 2014-06-30 |
| EP2768519A2 (en) | 2014-08-27 |
| JP2014533938A (ja) | 2014-12-18 |
| WO2013059778A3 (en) | 2013-07-04 |
| KR20150004791A (ko) | 2015-01-13 |
| US9555058B2 (en) | 2017-01-31 |
| SG11201401632WA (en) | 2014-05-29 |
| CN105999249A (zh) | 2016-10-12 |
| US20140308316A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201500784B (en) | Mycobacterial antigen vaccine | |
| SG10201911616QA (en) | Individualized vaccines for cancer | |
| IL232173A0 (en) | Cancer antigen presenting vaccine with gamma interferon | |
| IL231043A (en) | vaccine | |
| GB201120860D0 (en) | Cancer immunotherapy | |
| GB201003293D0 (en) | Cancer vaccine | |
| GB201119999D0 (en) | Vaccine | |
| ZA201402071B (en) | Vaccine therapy | |
| PL2591798T3 (pl) | Szczepionka do zastosowania w immunoterapii nowotworów | |
| PL3473267T3 (pl) | Zindywidualizowane szczepionki przeciwnowotworowe | |
| IL233928A0 (en) | A pluripotent germ layer-derived antigen with anti-cancer properties | |
| GB201120000D0 (en) | Vaccine | |
| GB201107549D0 (en) | Cancer vaccine | |
| GB201108256D0 (en) | Vaccine | |
| GB201121647D0 (en) | Vaccine | |
| GB201108986D0 (en) | Vaccines | |
| GB201108984D0 (en) | Vaccines | |
| GB201108982D0 (en) | Vaccines |